Background-Peroxisome proliferator-activated receptor gamma (PPARγ) is a transcription factor important for adipogenesis and adipocyte differentiation. Data from animal studies suggest that PPARγ may be involved in breast tumorigenesis, but results from epidemiologic studies on the association between PPARγ variation and breast cancer risk have been mixed. Recent data
Introduction
Peroxisome proliferator-activated receptor gamma (PPARγ) is a transcription factor important for adipogenesis and adipocyte differentiation (see review(1)). PPARγ is highly expressed in adipose tissue, with moderate expression in other tissues including heart, liver, and skeletal muscle (2, 3) . PPARγ signaling is known to be involved in lipid and glucose metabolism, and insulin sensitivity (1, 4). PPARγ activation has been reported to inhibit aromatase, an enzyme converting androgens to estrogens (5) . Consistent with this observation, a role of PPARγ signaling in inhibiting mammary tumorigenesis has been proposed in in vitro (6, 7) and animal studies (8, 9) , although a tumor-promoting effect of PPARγ in the mammary tissue has been also reported (10, 11) .
A common polymorphism in the PPARγ (rs1801282, Pro12Ala) has been shown to reduce PPARγ receptor activity and to be associated with impaired insulin sensitivity (12) , lower body mass index (BMI) (12) , and decreased colorectal cancer risk (13) . Five epidemiologic studies have examined this specific polymorphism (rs1801282) in relation to breast cancer risk and their results were mixed (14-18). Genome-wide association studies (GWAS) of breast cancer (19-25) have genotyped varying number of tagging SNPs in the PPARγ region (i.e. ∼10-∼40 PPARγ SNPs).PPARγ SNPs did not present a strong signal in these GWAS, including one GWAS conducted in an Asian population (21). However, true susceptibility loci may have been missed in these GWAS due to the limited statistical power (25, 26).
Mammographic density (MD) is a measure of the amount of epithelium and stroma relative to the amount of fat tissue in the breast, and is one of the strongest known predictors of breast cancer risk (27) . Women with greater than 75% MD have a 4-5 times higher risk of breast cancer than women of the same age with little or no density (<5%) (27) . MD has been shown to be influenced by both genetic (28) and non-genetic factors such as menopausal hormone therapy (29). Few genetic determinants of MD have been identified. A recent GWAS of MD among women of European descent, which is a meta-analysis of five unpublished GWAS of smaller sample sizes, identified one locus (ZNF365-rs10995190) associated with MD (30). To our knowledge, the role of PPARγ genetic variation on MD has not been investigated other than as a part of the GWAS of MD in Caucasian populations (30), where PPARγ was not reported to be associated with MD.
The influence of PPARγ genetic variation on MD may be different depending on the amount of exposure to a PPARγ ligand. Endogenous ligands for PPARγ are not yet clearly identified, although several fatty acid derivatives have been proposed as candidates (4, 31) . The most widely known exogenous ligands for PPARγ are anti-diabetics called thiazolidinediones (31). Another ligand of PPARγ is genistein, the major isoflavone present in soy beans (4) . High soy intake has been associated with lower breast cancer risk (32, 33) . While the effect of soy intake on MD is not consistent (34-39), we found a statistically significant inverse association between soy intake and MD in a well-defined, populationbased cohort of Chinese women in Singapore, using two different measurements of MD (38, 39) . Motivated by the genistein-PPARγ interaction and the inverse association between soy intake and breast cancer risk and possibly MD, we hypothesized that the association between PPARγ genetic variation and MD may interact with soy intake.
In the current study, we investigated the inter-relations of genetic variation in PPARγ, soy intake, and MD. To our knowledge, this study is the first to investigate the role of PPARγ genetic variation on MD in an Asian population.
Methods

Study Subjects
Details of the Mammography Subcohort who were women enrolled in both the Singapore Chinese Health Study (SCHS) and the Singapore Breast Screening Project (SBSP), have been described previously (39) . Briefly, the SCHS includes 35,298 Chinese women and 27,959 men, ages 45-74 years, who were enrolled during 1993-1998. Subjects were residents of government housing estates; during the enrollment period 86% of the Singapore population resided in such housing facilities. During 1994 to 1997, Singaporean women ages 50-64 years were invited for a screening mammography as part of the SBSP (40) . We identified 3,777 women common to the SBSP and SCHS databases through a computer linkage, and successfully retrieved mammograms of 3,702 women (98%). After excluding 6 women due to missing information on key variables and 1 woman who was later found not to be a Singapore resident, 3,695 women were included in the cross-sectional analysis of the Mammography Subcohort (38, 39, 41) .
Data Collection-At entry to the SCHS, a face-to-face interview was conducted in the subject's home by a trained interviewer using a structured questionnaire that asked about demographic and anthropometric factors, menstrual and reproductive history (women only), medical history, family history of cancer, use of tobacco, and other lifestyle factors. The questionnaire included a validated food frequency questionnaire (FFQ) in which each subject was asked to estimate his/her usual intake frequencies and portion sizes for 165 food and beverage items in the past 12 months (42) .Of the seven soy products (all are unfermented) and other food items included in the FFQ, the intake frequency categories were: never or hardly ever, 1-3 times/month, once/week, 2-3 times/week, 4-6 times/week, once/day, 2-3 times/day, 4-5 times/day, and 6 or more times/day. We expressed total soy intake in terms of soy isoflavones (38, 41) . We included only women without any history of cancer since lifestyle habits may change as a result of cancer diagnosis, and the presence of tumor and/or cancer treatment may additionally influence MD.
As part of the SBSP, participants completed a brief questionnaire that asked about demographic and body size characteristics and reproductive history. Since factors such as age, BMI, and menopausal status are established to be strongly associated with MD, we used the data collected at the same time the mammogram was performed, as part of the SBSP, for these analyses. The time interval between the dietary assessment at entry to the SCHS and the mammogram screening was minimal (median, 1.2 years; interquartile range, 0.8-1.8), and most of the study participants gave their dietary histories before the mammogram screening (39) .
Mammograms were assessed for density by one of the authors (GU) as previously described (39)using a highly reproducible computer-assisted method (29, 39, 41, 43) . In brief, subjects' mammograms were scanned using a Cobrascan 812T scanner (Radiographic Digital Imaging Inc., Compton, California) and Adobe Photoshop software with the plug-in program Scanwizard 3.0.9. Two research assistants trained by GU outlined the entire breast using an outlining tool on the computer screen, and the computer counted the total number of pixels, which represents the total breast area. The average of the two assistants' readings was used. The density readings were done by GU as follows: The reader draws a region of interest that excludes the pectoralis muscle and other artifacts. The software counts the number of pixels within the region of interest, which represents the area with absolute density. GU read the mammograms by random batches of 50, each of which included subjects of all age groups. The MD, or the mammographic percent density, is the absolute density (dense area) divided by the total breast area. Non-dense area was calculated by subtracting dense area from total breast area. Seven percent of the mammograms (n=237) had duplicate readings and the reproducibility on MD assessment was high (r=0.97, P <0.0001 for percent density; r=0.97, P<0.0001 for absolute density, r=0.99, P<0.0001 for total breast area).
The Institutional Review Boards at the National University of Singapore, the National Cancer Center, Singapore, the University of Southern California and the University of Minnesota had approved this study.
Blood Specimen Collection and DNA Extraction-In April 1994, one year after the initiation of the SCHS, we began collecting blood specimens from all consenting subjects drawn from a 3% random sample of enrollees. Red cells, plasma, serum, and buffy coat were extracted from blood. Subjects who refused to donate blood were asked to donate buccal cells using a mouthwash protocol. Eligibility for this biospecimen subcohort was extended to all surviving cohort participants starting in January 2000. By April 2005, samples were obtained from 32,535 subjects (∼60% participation). Of the 3,695 women evaluated for MD, DNA samples were available on 2,164 women (1,848 blood, 316 buccal). All extracted components from blood/mouthwash specimens were stored in -80C freezers until analysis.
Tagging SNP Selection and Genotyping-We selected tagging SNPs in the PPARγ, from 20kb upstream of 5′ untranslated region (UTR) to 10kb downstream of 3′ UTR. We tagged all common SNPs (minor allele frequency ≥5%) found among non-Hispanic white or Chinese populations, with R 2 ≥0.80. This selection was done using the Snagger (44)software and a custom database of the Hapmap CEU data (release 24) (45) merged with unique SNPs in the Affymetrix 500K panel as well as the Hapmap CHB data release 24.
We genotyped the selected SNPs in the PPARγ using the Illumina Golden Gate Assay (Illumina, Inc., San Diego, CA) at the University of Southern California Epigenome Core Facility, as a part of 384 SNPs in multiple candidate gene pathways. Of the 2,164 genotyped samples, 126 samples had a genotyping success rate (call rate) less than 85% and were excluded from the analyses; the final dataset for the current analyses thus included 2,038 samples. Genotyping concordance based on the 42 random duplicate samples was >99.9%. In the PPARγ region we genotyped 35 SNPs. Of these, we excluded 7 SNPs that had MAF<0.001 and 2 SNPs that had a SNP-call rate <85%, leaving 26 SNPs for analysis. All 26 SNPs did not depart significantly from Hardy-Weinberg equilibrium (HWE) (P≥0.01).
Statistical Analysis-We used linear regression to examine the association between PPARγ genotype and MD, adjusting for age at mammogram, BMI (kg/m 2 ) at mammogram, and dialect group (Cantonese, Hokkien). Additional adjustment for other breast cancer risk factors including parity, menopausal status, and hormone therapy use did not change the results; these risk factors were not included in the final model. Since MD and absolute density (i.e. dense area) had a skewed distribution, we evaluated whether square-root transformation of these variables change the results. The results were identical with regard to the magnitude and statistical significance of the regression coefficients, and therefore we present the results from the un-transformed density variables. The linear regression models were based on additive genetic models, where the regression coefficients are estimates of the difference in MD per copy of the minor allele of a given polymorphism. We then used a stepwise regression procedure to identify the most significantly associated SNP(s) among the SNPs that were statistically significantly associated with MD in a single SNP model (with P ACT <0.05). Starting from a model including age, BMI, and dialect, the most statistically significant SNP was allowed to enter the model, using model entry criterion of P<0.001 (uncorrected for multiple testing); this process was repeated until no additional SNP meets this entry criterion.
These analyses were repeated in subgroups defined by soy consumption (highest (4 th ) quartile versus lower 3 (1 st to 3 rd ) quartiles). Soy intake in the highest quartile (n=537) was >23.5 mg/day soy isoflavones (mean: 37.0 mg/day; median: 33.0 mg/day); soy intake in 1 st to 3 rd quartiles (n=1501) was ≤23.5 mg/day isoflavones (mean of the lowest 3 quartiles: 11.5 mg/day; median of the lowest 3 quartiles: 11.4 mg/day). These cutpoints were chosen because we previously showed that MD was decreased in women in the highest quartile of soy isoflavones (39) . We repeated the analysis on soy, PPARγ and MD by stratifying soy consumption at the median intake level (14.1 mg/day of isoflavones) and at a calorie-intake adjusted median level (i.e. 10mg/1000Kcal). Since the association between soy isoflavones and MD was limited to non-green tea drinkers in our previous report (39) , we also evaluated the PPARγ and MD association stratified by green tea drinking (non-drinker, monthly or more frequent drinker). We evaluated the interaction between BMI (<24, ≥24kg/m 2 ), parity (nulliparous and parous), menopausal status (premenopausal, postmenopausal), green tea (non-drinkers, ≥monthly) or soy consumption (≤23.5 mg/day soy isoflavones vs >23.5 mg/ day soy isoflavones) and PPARγ genotype by introducing product terms and conducting Wald tests, adjusting for age, BMI, and dialect. To correct for multiple testing, we calculated P values adjusted for multiple correlated tests (P ACT ) (46) .
Since genetic variation in PPARγ has been associated with Type 2 diabetes (47), and diabetes has been associated with increased breast cancer risk (48), we evaluated whether further adjustment for diabetes changes the results. Analyses were conducted using SAS 9.2 (SAS Inc., NC).All P values are two sided.
Results
Characteristics of the study participants
Compared to the excluded members of the subcohort (i.e., those without DNA samples), study subjects were more educated and more likely to be Cantonese, but otherwise similar to other subcohort members in factors such as age, BMI, parity, menopausal status, soy intake, and total caloric intake (Table 1) .
Genomic structure of PPARγ
The linkage-disequilibrium (LD) structure of PPARγ was assessed using the Hapmap dataset of Chinese population (Hapmap CHB data; release 27; Supplementary Figure 1 ) (45) . The 26 SNPs in the PPARγ that were analyzed in the current study tagged 90% of SNPs (MAF>0.01) in the Hapmap CHB dataset with pairwise R 2 >0.80. The average maximum pairwise R 2 was 0.98.
Association between PPARγ tagSNPs and MD
Nine of 26 tested PPARγ SNPs showed a nominal statistical significance (P values uncorrected for multiple testing < 0.01; Table 2 ). After correcting for multiple testing, 6 SNPs (rs880663, rs12629751, rs2292101, rs4135275, rs1151996, and rs796313) remained statistically significantly associated with MD. Minor alleles of five of the six SNPs are associated with decreased MD, and the estimated difference in MD per minor-allele ranges from 1.52% to 1.89%. When we used stepwise regression procedure including these 6 SNPs (with P ACT <0.05) with a model entry criterion of P<0.001 (uncorrected for multiple testing), only rs880663 remained in the final model. The results did not change when applying a more generous entry criterionP<0.01 (uncorrected for multiple testing). Rs880663 is correlated with the above five SNPs with pairwise R 2 ranging from 0.4 to 0.8.Of these SNPs, minor allele of rs4135275, which was associated with increased MD, was negatively correlated with the other SNPs (Supplementary Table 1 ). The distance between rs880663 and the other four SNPs ranged from 29kb to 79kb.
Stratified analyses by soy intake
When we performed subgroup analyses stratified by soy intake, the association between rs880663, the SNP selected during stepwise regression among all participants, and MD was considerably stronger among high soy consumers (Table 3) . MD decreased by 3.97% per copy of minor allele (G) of rs880663 (uncorrected P=0.0003; P ACT =0.006) among women in the highest quartile of soy intake. No statistically significant association between rs880663 and MD was observed in women consuming lower amounts of soy (P values for interaction with soy intake was 0.017 for rs880663; not corrected for multiple testing). Associations between other PPARγ SNPs (i.e. not selected during stepwise regression among all participants) and MD were also stronger among high soy consumers. Minor alleles of seven PPARγ SNPs associated with decreased MD were positively correlated with minor allele of rs880663, with a pairwise correlation coefficient ranging from 0.63 to 0.90 (P<0.0001 for all correlation coefficients; data not shown). Minor alleles of PPARγ SNPs associated with increased MD (rs4135275 and rs13076055) were negatively correlated with minor allele of rs880663, with a correlation coefficient of -0.64 and -0.71, respectively. When we ran stepwise regression models with the inclusion of rs880663, none of the other PPARγ SNPs was selected into the model with an entry criterion of P<0.001 (uncorrected for multiple testing). Application of a more generous entry criterionof P<0.01 (uncorrected for multiple testing) did not change the results. Among women with low soy intake, none of the PPARγ SNPs was associated with MD with an uncorrected P value of < 0.01. When soy intake was stratified with different cut points, similar patterns of effect modification were observed (data not shown).
Women in the subgroup of highest quartile of soy intake were more educated than women in the lower quartiles of soy intake, but were similar in age, BMI, parity, menopausal status, and MD (Supplementary Table 2 ). High soy consumers were more likely to drink green tea and had higher total food energy, obtaining more energy from protein and fat, and less from carbohydrate. When testing for the effect modification by these factors, there was no evidence that BMI, parity, menopausal status, or other nutritional characteristics associated with soy intake (green tea, protein, fat, and carbohydrate intake) modify the association between PPARγ SNPs and MD (data not shown). Further adjustment for diabetes did not change the results (data not shown).
Associations with absolute mammographic density and total breast area of mammogram
We also evaluated the association of PPARγ SNPs with absolute MD, total breast area and non-dense area on the mammogram (Supplementary Table 3 ). Per minor allele of rs880663, absolute density decreased by 1.2 cm 2 , whereas total breast area and non-dense area increased by 2.1 cm 2 and 3.3 cm 2 , respectively. When we repeated the analyses in the highsoy subgroup, absolute density decreased by 2.4 cm 2 per minor allele of rs880663; total breast area and non-dense area increased by 4.7 cm 2 and 7.0 cm 2 , respectively (data not shown).
Discussion
In this study of Singapore Chinese women, genetic variation in PPARγ was associated with MD; this association was significantly stronger in high soy consumers. To our knowledge, this is the first study investigating an association between PPARγ genetic variation and MD in Asians. Chinese women in Singapore rarely consume alcohol or use menopausal hormones, and have relatively low BMI compared to Western populations. Established determinants of MD (i.e. parity, BMI, age, menopausal status) are also found to be associated with MD in this population (39) .
It is well known that PPARγ signaling is important in adipocyte differentiation, glucose metabolism, and insulin sensitivity (1, 4). PPARγ signaling has been implicated in breast tumorigenesis in some studies, but conflicting evidence also exist (6) (7) (8) (9) (10) (11) . Several in vitro (6, 7)and animal studies (8, 9) have shown that activation of PPARγ signaling by ligandtreatment inhibits breast tumorigenesis. In line with these observations, PPARγ ligands were shown to inhibit aromatase activity in breast adipose stromal cells (5) . However, animal studies utilizing a constitutively-active mutant form of PPARγ have reported that PPARγ signaling may enhance oncogene-induced mammary tumor growth (10, 11) .
Five epidemiological studies focusing on a potentially functional polymorphism in PPARγ (rs1801282, Pro12Ala) in relation to breast cancer risk have reported mixed results including no association (14, 16, 17) , an inverse (15) or a positive (18) association with the variant allele. Rs1801282 is located 23kb downstream of rs880663, the SNP with the smallest Pvalue in our study. Rs1801282 and rs880663 are in low LD (r 2 <0.1) when evaluated using the Hapmap Chinese dataset, but rs1801282 is in high LD (r 2 >0.99) with two of our genotyped tagging SNPs (rs1899951 and rs2120825). However, neither of these two SNPs was associated with MD in our study. In the study conducted among Chinese women in Taiwan (17), the authors additionally genotyped two PPARγ SNPs (rs10865710 and rs3856806) that are in LD with rs1801282. These three PPARγ SNPs individually were unrelated to risk. When evaluating haplotypes constructed from these three SNPs linked to each other, several haplotypes were associated with increased breast cancer risk (17). The elevated risk associated with these 'at-risk' haplotypes could not be explained by the variation of any single genotyped SNP in the Taiwan study, suggesting that other PPARγ SNP(s) that were not genotyped in the Taiwan study may underlie the observed associations. In our study, variant allele of rs3856806, a marker of rs1801282, was associated with decreased MD with borderline statistical significance (P ACT =0.064), but the magnitude of association was weaker than that for rs880663 and several other SNPs. These findings suggest that PPARγ genetic variation is associated with MD and breast cancer risk, but rs1801282 is unlikely to be causally related to this association.
The role of PPARγ in the etiology of breast cancer (19-24) and MD (30) has been investigated as a part of several GWAS which included a range (∼10 to ∼40 SNPs) of PPARγ tagging SNPs.PPARγ was not reported to present a strong signal in any of the GWAS, including one conducted among Chinese in Shanghai, China, suggesting that genetic variation in the PPARγ region may not be associated with breast cancer risk or MD.
However, these GWAS could have missed true associations due to the lower statistical power (25, 26). Tagging coverage of the PPARγ region in four of these GWAS (20,23-25)was modest, presumably tagging (pairwise R 2 ≥0.8) less than ∼70% of SNPs in the PPARγ region with MAF >0.01, when evaluated using the Hapmap dataset (release 27) (45) and the SNP list on each genotyping array. In our current study, we were able to tag 90% of SNPs (with MAF>0.01) in the PPARγ region in the Chinese population. Finally, as mentioned above, all but one (21)of the GWAS of breast cancer (19,20,22-24)as well as the only published GWAS of MD (30)were conducted in populations of European decent, and thus have not addressed the role of genetic variation in Asians. Taken together, it is possible that PPARγ SNPs may be modestly associated with breast cancer risk in our study population, and our use of a quantitative trait (MD) related to breast cancer risk may have increased the statistical power to detect an association.
Since PPARγ is important in lipogenesis and PPARγ genetic variation has been associated with obesity (12), we speculated that the association between PPARγ and MD may be driven by the association with the non-dense area of the breast, a proxy measure of fat content, rather than with the absolute density, the cellular component. However, rs880663 and most other SNPs in PPARγ appeared to be inversely associated with absolute density and positively associated with total breast area and non-dense area (Supplementary table 3) , supporting that the PPARγ-MD relationship is not likely to be completely explained by the differences in fat component in the breast.
Our results show that the association between MD and the most significant SNP rs880663 as well as many of the other PPARγ SNPs was considerably stronger in women who were high soy consumers. While the most widely known activators of PPARγ are the antidiabetic drugs, fibrates and glitazones, it has been shown that genistein, the main soy isoflavones, can activate PPARγ (4). The effect of PPARγ genotypes on MD may be enhanced in the presence of higher levels of soy isoflavone. The estimated 3.97% difference in MD per minor allele of rs880663 (among high soy group) is not trivial, considering that two randomized clinical trials (29, 49) found that MD increased by 3-6% following one year treatment of estrogen-progestin combined hormone therapy, which is an established risk factor of breast cancer (50, 51) . MD is one of the strongest known predictors of breast cancer risk, and women with greater than 75% MD have a 4-5 times higher risk of breast cancer than women of the same age with little or no density (<5%) (27). Given this strong link between MD and breast cancer risk, it will be important in the future to study the relationship between soy and PPARγ on breast cancer risk.
To our knowledge, this study represents the first study to investigate genetic determinants of MD in a large, well-characterized population-based study of Asians. Our study sample size is 5-15 times larger than the few previous studies on genetic determinants of MD which included Asians (the largest previous study had ∼ 360 Asians) as part of their multi-ethnic population but in which Asian-specific analyses on MD were not conducted (52-54). Our results suggest an important association between PPARγ and MD which appeared to be modified by intake of soy food. However, given the lack of functional data on the investigated tagging PPARγ SNPs, our current study cannot directly address which SNP is the true causal variant driving the SNP-MD association. Another limitation is that rs1801282 (Pro12Ala; MAF of 2% in Hapmap Chinese population) was not included in our tagging SNP selection, thus precluding direct comparison of our findings with those from other epidemiologic studies of PPARγ on breast cancer risk. Nonetheless, we genotyped two SNPs (rs1899951 and rs2120825) that are highly correlated with rs1801282, and we found no associations with MD or absolute or non-dense area. Our findings are in line with the results from a study of Chinese women in Taiwan showing that overall PPARγ genetic variation, but not rs1801282 or two other SNPs genotyped in the study individually , was associated breast cancer risk in Chinese women (17).
In conclusion, our data from a Singapore Chinese population support that PPARγ genetic variation may be important in determining MD, particularly in high soy consumers.
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